Mr. Ron Nagar reports

TEMPRAMED UPLISTS TO OTCQB VENTURE MARKET AND ACHIEVES DTC ELIGIBILITY, EXPANDING ACCESS TO U.S. INVESTORS

Tempramed Technologies Ltd.'s common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The company's shares are also now DTC eligible, significantly enhancing the accessibility and efficiency of trading for United States investors.

Tempramed common shares trade on the OTCQB under the symbol TMPTF while continuing to trade on the Canadian Securities Exchange (CSE) under the symbol VIVI.

The company's OTCQB uplisting, combined with DTC eligibility, represents an important milestone in expanding Tempramed's presence within the U.S. capital markets, improving trading accessibility, increasing liquidity potential, and broadening the company's visibility among retail investors, institutional investors, family offices and investment advisers throughout North America.

"Our uplisting to the OTCQB is an important step in Tempramed's evolution and significantly expands access for U.S. investors to participate in a growing health care industry and technology company focused on temperature-sensitive medications," said Ron Nagar, chief executive officer of Tempramed. "While we are already executing a U.S.-focused growth strategy through domestic manufacturing, expanding national distribution partnerships and an accelerating pharmacy rollout, the OTCQB listing provides greater visibility and accessibility for the broad U.S. investment community. As our commercial momentum continues to build with leading health care organizations, we believe this enhanced market presence better aligns our shareholder base with where we are creating value. We are building a scalable health care platform with significant long-term growth opportunities, and we are excited to provide U.S. investors with greater access to participate in our next phase of expansion."

DTC eligibility enables electronic settlement of the company's common shares through the Depository Trust Company, reducing costs and accelerating the clearing and settlement process for U.S. broker-dealers and investors. The OTCQB is recognized by the U.S. Securities and Exchange Commission as an established public market and is designed for entrepreneurial and growth-stage companies committed to providing high-quality disclosure and transparency.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered, space-grade thermal insulation devices that work 24/seven without batteries or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, anytime. Headquartered in Israel with operations in North America, Europe and Asia, Tempramed is advancing the future of medication protection and adherence.

We seek Safe Harbor.